Shanghai Henlius Biotech, Inc.
2696
Rang în acțiuni
#4222
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Preț acțiune
$6.89
Capitalizare de piață
$3.76B
Schimbare (1 zi)
2.96%
Schimbare (1 an)
-27.06%
Țară
CN
Tranzacționează Shanghai Henlius Biotech, Inc. (2696)
Categorie
Healthcare
Număr de acțiuni în circulație pentru Shanghai Henlius Biotech, Inc. (2696)
Număr de acțiuni în circulație la data de June 2026: 544.86M
Conform celor mai recente rapoarte financiare și prețului acțiunilor Shanghai Henlius Biotech, Inc., numărul curent de acțiuni în circulație este 544.86M. La sfârșitul anului December 2023, compania avea 546.02M acțiuni în circulație. Numărul de acțiuni în circulație este de obicei influențat de splituri de acțiuni și programe de răscumpărare.
Istoricul acțiunilor în circulație pentru Shanghai Henlius Biotech, Inc. (2696) din 2017 până în 2026
Acțiuni în circulație la sfârșitul fiecărui an
| An | Acțiuni în circulație | Schimbă |
|---|---|---|
| 2026 (TTM) | 544.86M | 0.25% |
| 2024 | 543.50M | -0.46% |
| 2023 | 546.02M | 0.74% |
| 2022 | 542.02M | 0.80% |
| 2021 | 537.73M | 1.75% |
| 2020 | 528.48M | 6.30% |
| 2019 | 497.16M | -4.53% |
| 2018 | 520.74M | -3.41% |
| 2017 | 539.13M | 0.00% |
Acțiuni în circulație pentru companii similare sau concurente
| Companie | Acțiuni în circulație | Diferență | Țara |
|---|---|---|---|
| 253.90M | -53.40% |
US
|
|
| 396.00M | -27.32% |
US
|
|
| 478.91M | -12.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -88.59% |
NL
|
